Sterilization Validation Evidence for Canadian Submissions

1. Key takeaways

The Canadian dossier for a sterile device must present a five-link evidence chain: the selection and suitability of the sterilization method; sterilization validation, meaning the establishment and verification of the dose or cycle; routine monitoring; packaging integrity, meaning validation of the sterile barrier system; and shelf life, including evidence of the period over which sterility is maintained. The links are sequential and interdependent: the method determines what validation looks like, validation defines what monitoring measures, and the packaging and shelf-life evidence determines how long the validated state can be claimed. On top of this technical chain sits a labelling duty: the word Sterile must appear on the label under section 21(1)(f) of the Medical Devices Regulations whenever the manufacturer intends the device to be sold in a sterile state.

• The dossier follows a five-link chain: method, validation, routine monitoring, packaging integrity, shelf life.
• Validation covers establishment and verification of the sterilization dose or cycle.
• The sterile barrier system validation (typically ISO 11607 series) is tied to shelf-life testing.
• Section 21(1)(f) requires the word Sterile on the label for devices sold in a sterile state.
• Section 21(1)(g) sets expiry dating by the component with the shortest expected service life.
• Contract sterilizers are verified separately and listed in the supplier information (MDEL supplier information from 2026-12-14).

2. Legal basis

The sources below combine the labelling provisions of the Medical Devices Regulations that apply directly to sterile devices, the general safety and effectiveness provisions they hang from, and the consensus standards commonly used for sterilization and packaging. All Regulation provisions were verified against Justice Laws; the standards are cited as consensus standards throughout.

3. Expert insights

Insight 1: Sterile is a mandatory labelling item and the mirror image of sterilization validation.

Under section 21(1)(f), a device the manufacturer intends to sell in a sterile condition must carry the word Sterile on its label. The two directions of this rule deserve equal attention. Once the claim is made, validation evidence for the sterilization process must exist to support it; conversely, where validation evidence does not exist, no sterile claim may be made on the label. A sterile claim is therefore not a marketing choice to be added late in the labelling process — it is a commitment that pulls the entire five-link evidence chain behind it. Teams should decide early whether the device will be sold as sterile, because that decision shapes the validation programme, the packaging development and the shelf-life testing plan from the beginning.

Insight 2: the rule for determining expiry dating is written in the Regulation.

Under section 21(1)(g), where a device has an expiry date, that date is determined by the manufacturer on the basis of the component with the shortest expected service life. This rule binds the expiry date to component life rather than leaving it to commercial preference. It means the technical file must identify which component limits the shelf life and show the evidence — ageing data, stability data, component analysis — that supports dating the whole device by that component. An expiry date chosen to suit sales planning, without the shortest-service-life analysis behind it, does not satisfy the provision and will not survive a request for the supporting rationale. Documenting the limiting component and its evidence makes the dating decision transparent and reviewable.

Insight 3: packaging integrity and shelf life should be considered together.

Validation of the sterile barrier system, typically performed against the ISO 11607 series, should be planned jointly with shelf-life verification. Accelerated ageing and real-time ageing programmes both use packaging integrity as one of their endpoint measures: the question the ageing study answers is not only whether the device still performs, but whether the barrier still protects sterility at the end of the claimed period. Running the two programmes separately — packaging tested at release, shelf life assessed on the device alone — leaves the decisive question unanswered: whether the sterile state persists to the expiry date. Joint planning aligns the ageing conditions, the test intervals and the acceptance criteria so that one coherent dataset serves both claims.

Insight 4: when sterilization is performed by a contract sterilizer, the entity status must be verified separately.

Canada brings contract sterilizers and similar entities within the scope of MDEL-related considerations. Where sterilization is performed by a contract manufacturer or a third party, the licensing status of that site must be verified on its own; the client’s licence does not cover the sterilizer’s facility. The verification should be recorded, the site added to the supplier information, and the arrangement revisited when contracts or sites change. From 2026-12-14, the MDEL must include supplier information, which makes the contract sterilizer a named entry in the licence documentation rather than an implicit assumption buried in a supply agreement.

4. Practical recommendations

• Build the evidence chain in five segments — method, validation, monitoring, packaging, shelf life — and archive each segment as it is completed.
• Keep the word Sterile on the label in one-to-one correspondence with the sterilization validation evidence.
• Determine the expiry date by the component with the shortest expected service life and record the analysis in the technical documentation.
• Make packaging integrity one of the endpoint measures of the shelf-life verification programme.
• Verify the contract sterilizer’s status separately and add it to the supplier information list (MDEL supplier information required from 2026-12-14).

5. Verification checklist

• □ The rationale for the choice of sterilization method is documented.
• □ Sterilization validation (dose or cycle) is complete and archived.
• □ A routine monitoring plan is established.
• □ Packaging integrity validation is complete.
• □ Shelf-life verification includes packaging integrity as an endpoint, and the date follows the rule in section 21(1)(g).
• □ The word Sterile on the label matches the validation evidence.
• □ The contract sterilizer has been added to the supplier information list.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com